Mineralys Therapeutics
- Market cap
- 1.95B
- P/E (TTM)i
- -5.26
- P/Bi
- 3.54
- EPSi
- -2.29
- Div yieldi
- 0.00%
- 52W posi
- 2%
Anonymous reader poll. Unscientific, not investment advice.
Mineralys Therapeutics shares were changing hands at 22.09, up 0.64% on the day. The company carries a market value of roughly 1.95B, the #2760 most valuable US-listed company we track. Across 6 analysts the consensus rating is Buy, with an average price target of 51.00 (+131%). Against a 52-week band of 21.49-47.65, the shares are currently 2% of the way up.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 4 weeks.
- Its last 6 Sell calls were actually followed by a +36% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -34.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 21.95
- Open
- 21.78
- Day range
- 21.49 - 22.44
- Avg price
- 22.17
- Volume
- 989.12K
- Turnover
- 21.93M
- Turnover ratei
- 1.49%
- Volume ratioi
- 0.71
- Amplitudei
- 4.35%
- 52-week rangei
- 21.49 - 47.65
Valuation
- P/Ei
- -9.65
- P/E (TTM)i
- -5.26
- P/Bi
- 3.54
- EPSi
- -2.29
- Book value / shi
- 6.23
- Net profit
- -202.45M
- Net assets
- 550.95M
Share structure
- Market cap
- 1.95B
- Float capi
- 1.47B
- Shares out
- 88.41M
- Float sharesi
- 66.60M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2023-02-10
53.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.45M net over the window
Short interest
- Shares short
- 9.18M
- % of floati
- 10.39%
- Days to coveri
- 6.36
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Mineralys Therapeutics (MLYS)?
Mineralys Therapeutics last traded at 22.09. The quote on this page refreshes every few seconds while US markets are open.
What is Mineralys Therapeutics's market cap?
About 1.95B.
What is the P/E ratio of Mineralys Therapeutics?
The trailing twelve-month P/E is -5.26. The Valuation tab shows it against the stock's own five-year range.
Does Mineralys Therapeutics pay a dividend?
Mineralys Therapeutics does not currently pay a regular dividend.
Is Mineralys Therapeutics a buy according to analysts?
The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 51.00, which implies 130.9% upside from the current price. This is not investment advice.
What is Mineralys Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Mineralys Therapeutics a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-10-08 06:33:06 · For reference only, not investment advice and not tailored to your situation.